Neoplasms

All Conditions

Adenocarcinoma

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

LY011

Jun Song, Chief physician

June Song

Li Li

Objective to evaluate the safety and efficacy of ly011 cell injection in the treatment of advanced gastric adenocarcinoma.

A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma

to Evaluate the Safety and Efficacy of LY011 Cell Injection（Targeting CLDN 18.2 Chimeric Antigen Receptor T Cells） in the Treatment of Advanced Gastric Adenocarcinoma

MTD determination will based on the incidence of reported adverse events (including dose-limiting toxicities) and abnormal laboratory test results.

the proportion of patients with best overall response of complete response (CR) or partial response (PR), as per local investigator´s assessment and according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria

Area under the curve from time 0 to the last time point for serum CAR-T cells

Maximum concentration for serum CAR-T cells

Area under the serum concentration-time curve for serum CAR-T cells

Time to maximum concentration for serum CAR-T cells

Terminal elimination rate constant for serum CAR-T cells

Area under the curve above baseline of ANC for serum CAR-T cells

The Affiliated Hospital of Xuzhou Medical University

Shanghai Longyao Biotechnology Inc., Ltd.

Digestive System Diseases

Gland and Hormone Related Diseases

Rare Diseases

Pancreatic Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Endocrine Gland Neoplasms

Gastrointestinal Diseases

Pancreatic Diseases

Endocrine System Diseases

Pancreatic Cancer

Bin Liu

Wenxing Zhao

CLDN 18.2 chimeric antigen receptor T cells Clinical research plan for the treatment of recurrent or refractory pancreatic cancer.

Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer

A Study of CLDN18.2 Chimeric Antigen Receptor T Cells in the Treatment of Advanced Pancreatic Cancer

Survival witouth observed progression at 2 years

DOR was defined as the time from the first documented a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: ≥30% decrease in the sum of diameters of target lesions) to progressive disease (PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study to Evaluate the Safety and Efficacy of ly011 Cell Injection in the Treatment of Advanced Gastric Adenocarcinoma	NCT04977193	Advanced Gastri...	LY011	18 Years - 70 Years	Shanghai Longyao Biotechnology Inc., Ltd.
Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer	NCT04966143	Pancreatic Canc...	LY011	18 Years - 70 Years	Shanghai Longyao Biotechnology Inc., Ltd.
Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer	NCT04966143	Pancreatic Canc...	LY011	18 Years - 70 Years	Shanghai Longyao Biotechnology Inc., Ltd.

Spots Global Cancer Trial Database for ly011

Every month we try and update this database with for ly011 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for ly011

Every month we try and update this database with for ly011 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for ly011 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.